Breast Cancer Prevention
Breast Cancer Prevention
Prevention in breast cancer is mostly about finding the disease at the stage when treatment is simplest, and for a small group of women it also includes measures that reduce the chance of developing it at all.
Screening: what it finds, and when to start
Mammography is the only screening test for breast cancer that has been shown in randomised trials to reduce deaths from the disease, and it works by finding tumours years before they can be felt. Its benefit is largest where it is repeated on schedule, because the comparison with previous images is part of how a mammogram is read.
-
Average risk
Begin mammography at around 40 and repeat every one to two years. In China, organised screening programmes also cover defined age groups. Where breast tissue is dense, ultrasound is added — a combination that improves detection in exactly the group in which mammography alone is weakest.
-
Moderately increased risk
A first-degree relative with breast cancer, previous atypical hyperplasia, or previous chest radiotherapy. Imaging begins earlier, intervals are shorter, and the plan is set by a specialist rather than by an age-based programme.
-
High genetic risk
A known BRCA1, BRCA2 or other high-penetrance mutation. Annual MRI from a young age, usually alternating with mammography, is the standard, and the discussion extends beyond imaging to risk-reducing options.
The interval matters as much as the starting age. A mammogram taken once is a snapshot; mammograms taken on schedule allow the reader to see what has changed, and change is often the earliest sign. If a symptom appears, it is investigated on its own timetable and does not wait for the next screening appointment.
Working out which schedule applies to you
Guidelines organise screening by risk group, so the practical first step is establishing which group you are in. That takes a structured conversation rather than a general recommendation.
Bring these to a risk assessment:
- Family history across three generations — who was affected, on which side of the family, at what age, and whether there was ovarian cancer or male breast cancer
- Your own breast history — any previous biopsy, and what it showed, particularly atypical hyperplasia or lobular carcinoma in situ
- Previous chest radiotherapy — the reason for it, and the age at which it was given
- Any genetic test results — yours, or those of an affected relative if they are available
- Breast density from your last mammogram — usually stated in the report, and it determines whether ultrasound is needed
Surveillance for high genetic risk
Where a high-penetrance mutation is confirmed, surveillance is intensified and starts young. The pattern below reflects international practice; the exact ages are set individually with the genetics and breast teams.
-
Annual MRI from the mid-twenties to thirties
MRI detects tumours in dense, young breast tissue that mammography reads poorly. In carriers it is the primary surveillance method from the age at which the risk begins to rise, determined by the specific gene.
-
Mammography added from around age 30
Usually alternating with MRI at six-month intervals rather than replacing it. The two tests are complementary in this group, and doing both is what the risk justifies.
-
Ovarian surveillance, and the conversation about surgery
BRCA mutations raise ovarian cancer risk as well, and surveillance for that is arranged in parallel. The option of risk-reducing surgery is discussed early rather than deferred, because its timing interacts with decisions about childbearing and with the effectiveness of the measures available.
Measures that reduce risk, and who they are for
For most women, the measures below are not applicable or not worth their costs. For a small group at the highest risk they are realistic options, and they should be discussed rather than discovered later.
| Measure | Who it is considered for | What to weigh |
|---|---|---|
| Risk-reducing mastectomy | Confirmed high-penetrance mutation, or a very strong family history | Substantially reduces but does not eliminate risk; irreversible; reconstruction can be performed at the same time |
| Risk-reducing salpingo-oophorectomy | BRCA1 or BRCA2 carriers, after childbearing | Reduces ovarian cancer risk, and in premenopausal carriers also reduces breast cancer risk; induces menopause |
| Endocrine risk-reducing therapy | Women at increased risk from atypical hyperplasia, LCIS, or a strong family history | Reduces the incidence of hormone receptor-positive breast cancer; requires a multi-year commitment and has menopausal side effects |
| Intensified imaging alone | Increased risk where surgery and drug prevention are not appropriate | Finds disease earlier but does not prevent it; a legitimate choice that should not be treated as a refusal of care |
These options apply only to defined risk groups. For women at average risk, the appropriate preventive measure is screening on schedule, not surgery or drug prevention.
Lifestyle measures and how much they change
The modifiable factors are limited and their effects are modest compared with age and inherited risk. That is worth saying plainly, because overstating them turns prevention into a burden of blame instead of a set of choices.
-
Alcohol
Risk rises with the amount consumed and the association is present even at lower intakes. Reducing consumption is one of the clearer modifiable steps available.
-
Weight and activity
Higher body weight after menopause and physical inactivity are both associated with higher risk. Regular moderate activity is associated with lower risk, largely independent of weight.
-
Hormone therapy decisions
Prolonged combined hormone therapy is associated with higher risk. Where it is being considered for menopausal symptoms, the duration and the preparation are worth a specific conversation with the prescribing clinician.
Breastfeeding is associated with a modest reduction in risk, and for women who have the choice, it is one of the few reproductive factors that moves in a favourable direction. None of this replaces screening.
What screening can and cannot do
Screening is not infallible, and understanding its limits is part of using it well.
-
What it does well
It finds cancers earlier, on average, than waiting for symptoms, which means more breast-conserving surgery, less chemotherapy, and better survival in the group screened. It finds in situ disease before it becomes invasive, and it detects tumours in the opposite breast when a patient is already being treated.
-
Where it falls short
Dense tissue hides tumours; some cancers grow quickly between intervals and are found despite a recent normal test; and some findings turn out to be benign, leading to further tests and anxiety. Interval cancers and false positives are known limitations, not evidence that screening does not work.
-
A normal mammogram after a change
A new lump or skin change needs assessment even if a recent mammogram was normal. Imaging is a test, not a certificate, and symptoms take precedence over a previous result.
-
Screening is not for diagnosis
Diagnostic imaging for a symptom is a separate pathway with different protocols and reporting. Mixing the two leads to delays, which is why a symptom should be referred to a diagnostic clinic rather than to the next screening round.
These distinctions are set out in more detail, alongside what each test can answer, in how breast cancer is diagnosed.
Building your own plan
A surveillance plan is a schedule with a reason behind each element, and it should be written down so that it can be followed wherever you are. The elements below cover what a plan typically contains.
-
Establish your risk group, once
Family history, personal breast history, genetic results if any, and breast density. This is done once and revisited when something changes, rather than decided afresh at each appointment.
-
Set the modality and the interval
Mammography alone for most women; mammography plus ultrasound where tissue is dense; MRI-led surveillance for high genetic risk. The interval follows from the risk group and is not adjusted by anxiety or by convenience.
-
Decide what happens if something is found
Know in advance where a suspicious finding would be assessed and by whom. Being referred promptly is a property of the plan, not luck.
-
Keep the images
Retain every mammogram, ultrasound and MRI in digital form. Comparison with previous studies is one of the most informative things a reader does, and images left behind when moving between hospitals cannot be compared. For women who have already been treated for breast cancer, surveillance has an additional purpose — detecting recurrence — and the schedule is different. That is covered in the practical questions page, alongside follow-up arrangements after treatment abroad. The factors behind the risk estimates used above are set out in causes and risk factors.